FIG. 8.

RhoB deletion compromises the antitumor efficacy of FTIs. (A) Xenograft assay. +/− and −/− E1A- plus Ras-transformed cells were injected subcutaneously into opposite thighs of each of 16 SCID mice. Mice were assigned randomly to drug treatment or control groups and 1 week later were dosed daily for 16 days by intraperitoneal injection with FTI L-744832 (40 mg/kg) or vehicle carrier as described in the text. Tumor size was measured by caliper, and tumor volume was computed as described in Materials and Methods. The data represent the average tumor volumes ± standard errors of the means computed at the times indicated. (B) Representative tumors from control or drug treatment animals. Tumors were excised at the end of the experiment from euthanized animals and fixed in formalin before being photographed.